The frequent occurrence of ER mutations in hormone therapy-resistant ER-positive metastatic breast cancer has led to intense research efforts to elucidate the molecular and phenotypic effects of ER mutations and to identify vulnerabilities in ER mutant cancers that could be exploited to develop effective therapies for hormone therapy-resistant tumors (4–18). This evidence concerns the gene ESR1 and breast cancer.